联合检测食管鳞癌放疗前后血清SCC、VEGF、CYFRA21-1的临床意义

目的：探讨联合检测食管鳞癌患者血清鳞状上皮细胞癌相关抗原（SCC）、血管内皮生长因子（VEGF）、细胞角化素蛋白片段19（CYFRA21-1）对放疗效果评估的价值。方法：采用酶联免疫吸附法（ELISA）或电化学发光免疫分析法（ECLIA）测定80例食管鳞癌患者放疗前、后血清SCC、VEGF、CYFRA21-1水平,并以20例健康者为对照。结果：食管鳞癌组血清SCC、VEGF、CYFRA21-1水平明显高于对照组,食管鳞癌组血清SCC、VEGF、CYFRA21-1对放疗后有效者（CR＋PR）均明显低于放疗前（P〈0.05）。结论：血清SCC、VEGF、CYFRA21-1联合检测食管鳞癌放疗疗效和预后判断有较好的临床应用价值。

Signifcance of combined determination of SCC,VEGF and CYFRA21-1 in peripheral blood of patients with esophageal squamous cell carcinoma before and after radiotherapy

Objective：To evaluate whether the detection of SCC combined with VEGF and CYFRA21-1 in esophageal squamous cell carcinoma patients treated by radiotherapy would reflect the prognosis of esophagus carcinoma.Methods： Serum SCC,VEGF and CYFRA21-1 were determined by enzyme linked immunosorbent assay（ELISA）and（or） Electrical chemiluminescent immunoassay（ECLIA）in 80 patients with esophageal squamous cell carcinoma treated by radiation therapy（RT group）and in 20 healthy controls.Results：The concentrations of serum SCC,VEGF and CYFRA21-1 were significantly higher in the trial group than those in the control group（P〈0.05）.In the trial group,the concentrations of SCC,VEGF and CYFRA21-1 at each stage during radiotherapy were significantly lower than those before radiotherapy（P〈0.05）.Conclnsion： Combined detection of SCC,VEGF and CYFRA21-1 is hel pful to prognosis evaluation of esophageal squamous cell carcinoma patient treated by radiation therapy.